If you missed some (or all) of #DDW2024, let us help you catch up, beginning with this recap from Miguel Regueiro on disparities in IBD care among non-English speakers: hmpgloballearningnetwork.com/site/aibdnet/m…

Listen to the new #IBD Drive Time as Francis (Frank) Farraye, MD, MSc reviews his choices for the best abstracts from ECCO with hosts Millie Long and Raymond Cross: hmpgloballearningnetwork.com/site/aibdnet/p…

See what David T. Rubin, MD reported at #DWW about the maintenance study of guselkumab in ulcerative colitis: hmpgloballearningnetwork.com/site/aibdnet/d…

Among the challenges of treating IBD is determining the right drug for the right patient. David T. Rubin, MD provides guidance in his talk from the postgraduate session at #DDW: hmpgloballearningnetwork.com/site/aibdnet/v…

FDA approves risankizumab for moderate to severe ulcerative colitis. hmpgloballearningnetwork.com/site/aibdnet/f…

Gout is the most common inflammatory arthritis in the US, but it still presents treatment challenges. Drs Vikas Majithia and Ronald Butendieck from Mayo Clinic-Florida discuss here: hmpgloballearningnetwork.com/site/rheum/pod…

Don't miss the latest IBD Drive Time podcast as hosts Raymond Cross and Millie Long begin a 2-part review of the Best of DDW! hmpgloballearningnetwork.com/site/aibdnet/p…

Don't miss part 2 of IBD Drive Time's Best of DDW as Dr Millie Long chooses her top picks: hmpgloballearningnetwork.com/site/aibdnet/p…

AIBD Regional Meeting is underway in Chicago! Check back for updates.

“The safest treatment is often the treatment that effectively controls ulcerative colitis," Dr Christina Ha told the attendees at the AIBD regional meeting in Chicago. hmpgloballearningnetwork.com/site/aibdnet/c…

Dr Ray Cross Raymond Cross discussed using comparative effectiveness studies to help position therapies for patients with ulcerative colitis at the #AIBD regional meeting in Chicago: hmpgloballearningnetwork.com/site/aibdnet/r…

Exciting news for PBC patients! The FDA has approved Livdelzi (seladelpar) – a significant advancement in therapy options. It's incredible to see the progress being made in the treatment of this rare disease. #PBC #Livdelzi #FDAapproval

In support of HMP Global's Day of Giving, a portion of today's Advances in IBD registrations will be donated to Stop Soldier Suicide, working to solve the issue of suicide among U.S. veterans and service members. Register now! hmpglobalevents.com/aibd/rates

Subcutaneous Ustekinumab Cost Rose 84% Under Medicare Part D, Set to Drop Under Negotiated Price Reduction. Read about it here: hmpgloballearningnetwork.com/site/aibdnet/s…

At the inaugural APP Institute Inflammatory Bowel Disease, Alexis Oonk, FNP, reviewed how to establish a diagnosis of inflammatory bowel disease. Dive into diagnostics here! hmpgloballearningnetwork.com/site/ibd-app/v…

Don't miss the latest IBD Drive Time, as guest Erin Forster MD MPH Erin Forster MD talks with hosts Raymond Cross Ray Cross and Millie Long Millie Long about risankizumab for ulcerative colitis. hmpgloballearningnetwork.com/site/aibdnet/p…

Don't miss the latest Gut Check podcast as host Dr Brian Lacy discusses antireflux surgery with guest Rena Yadlapati: hmpgloballearningnetwork.com/site/gastro/po…

We are thrilled to announce the 2024 Sherman Prize Recipients, Millie Long, UNC-Chapel Hill UNC School of Medicine UNC Gastroenterology & Dr Dermot McGovern, IBD at Cedars-Sinai Cedars-Sinai, & the Emerging Leader Prize Recipient, Jordan Axelrad, MD, MPH, NYU Langone Health NYU Grossman School of Medicine. Learn more about the honorees at ShermanPrize.org

Congratulations to the winners of this year's Sherman Prize--Millie Long, MD, from the University of North Carolina, and Dermot McGovern, MD, from Cedars-Sinai , and to Emerging Leader winner Jordan Axelrad, MD, from NYU-Langone. Well deserved for each of you!

How do you treat acute severe ulcerative colitis? Hear what Dr Millie Long Millie Long has to say: hmpgloballearningnetwork.com/site/aibdnet/h…